Small-bowel bleeding
Small-bowel bleeding, formerly called obscure gastrointestinal bleeding, arises between the ampulla of Vater and the ileocecal valve and is defined by a source not found on initial bidirectional endoscopy. Angiodysplasia predominates over age 40 while Meckel diverticulum, tumors, and inflammatory bowel disease predominate below 40, and video capsule endoscopy after second-look endoscopy is the diagnostic pivot, with device-assisted enteroscopy and CT or catheter angiography reserved for localization and therapy.
- Topic reviewThe full article, organized the way the exam asks it.
- ABIM-format MCQsVignettes with an explanation for every wrong answer.
- Key factsThe numbers and thresholds worth memorizing, up front.
- AI tutorMedBrain answers the question you're stuck on.
What this article covers
- Overview
Definition: small-bowel bleeding is gastrointestinal bleeding from a source between the ampulla of Vater and the ileocecal valve, previously termed obscure gastrointestinal bleeding, defined…
- Epidemiology
Proportion of GI bleeding: small-bowel sources account for 5% to 10% of gastrointestinal bleeding.
- Risk factors
Age over 40: shifts the cause toward angiodysplasia, Dieulafoy lesions, neoplasia, and NSAID-related ulcers.
- Pathophysiology
Angiodysplasia: acquired ectatic, thin-walled submucosal and mucosal vessels, believed to arise from chronic low-grade venous obstruction with age-related degeneration, producing fragile fernlike lesions on capsule endoscopy.
- Clinical features
Overt bleeding: melena or hematochezia without an identified upper or lower source on bidirectional endoscopy.
- Differential diagnosis
Missed upper GI lesion: a peptic ulcer or gastric antral vascular ectasia overlooked on a low-quality initial EGD, discriminated by second-look upper endoscopy (peptic ulcer disease).
- Diagnosis
Diagnosis is established operationally, not by a scoring system: small-bowel bleeding is confirmed when a source is not identified on an adequate initial upper endoscopy and colonoscopy in a patient…
- Management
Stabilize first: assess hemodynamic status, resuscitate with IV fluids and blood products as needed, and correct coagulopathy before definitive localization.
- Complications
Recurrent or persistent bleeding: angiodysplasia and Dieulafoy lesions recur despite endoscopic therapy in a meaningful proportion of patients, driving transfusion dependence.
- Prognosis
Course depends on the cause: focal, treatable lesions such as an accessible angiodysplasia, Dieulafoy lesion, or Meckel diverticulum have a good prognosis after directed endoscopic or surgical therapy.
- Prevention
Stop and avoid NSAIDs in any patient whose small-bowel bleeding is attributed to NSAID-related ulceration or erosion.
Read the whole article
Subscribing to Internal Medicine opens every article, the full question bank and MedBrain, on the web, iPhone and Android.
Related articles
- Acute upper gastrointestinal bleeding
Acute upper gastrointestinal bleeding arises proximal to the ligament of Treitz and presents with hematemesis or melena, most often from peptic ulcer disease or bleeding gastroesophageal varices. Management sequences resuscitation, restrictive transfusion, IV proton pump inhibitor therapy, and, when varices are suspected, octreotide plus antibiotic prophylaxis, all before upper endoscopy within 24 hours, which is both diagnostic and therapeutic.
- Acute lower gastrointestinal bleeding
Acute lower gastrointestinal bleeding is hematochezia from a source distal to the ligament of Treitz, most often diverticular, that requires simultaneous resuscitation and localization because a brisk upper source can masquerade as the same presentation. Colonoscopy after rapid bowel preparation is the first-line diagnostic and therapeutic study in stable patients, while CT angiography localizes active bleeding in unstable or rapidly bleeding patients before catheter embolization or surgery.
- Peptic ulcer disease
Peptic ulcer disease is a mucosal break in the stomach or duodenum caused chiefly by Helicobacter pylori infection or NSAID use, diagnosed by upper endoscopy with biopsy of gastric ulcers to exclude malignancy. Treatment eradicates H. pylori when present, stops the ulcerogenic drug, and heals the ulcer with a proton pump inhibitor, while its complications of bleeding, perforation, and obstruction drive most of its morbidity.
- Crohn disease
Crohn disease is a chronic transmural inflammatory bowel disease that can affect any segment from mouth to anus in skip lesions, most classically the terminal ileum, and is confirmed by ileocolonoscopy showing cobblestoning, skip areas, and non-caseating granulomas on biopsy. Management follows an ordered sequence of glucocorticoid or budesonide induction followed by immunomodulator or biologic maintenance, with surgery reserved for fixed complications rather than cure.
- Nonsteroidal anti-inflammatory drugs
Nonsteroidal anti-inflammatory drugs (NSAIDs) relieve pain, fever, and inflammation by inhibiting cyclooxygenase (COX)-1 and COX-2, and that single mechanism predicts every major toxicity: gastric ulceration, platelet dysfunction, and hemodynamic renal injury. First-line agents are naproxen or ibuprofen (or topical diclofenac for knee or hand osteoarthritis) at the lowest effective dose for the shortest duration, with a proton pump inhibitor such as omeprazole 20 mg once daily added for patients at increased gastrointestinal risk.
- Carcinoid syndrome
Carcinoid syndrome is the clinical syndrome of episodic flushing, secretory diarrhea, and late right-sided valvular heart disease caused by serotonin and other vasoactive amines escaping hepatic first-pass metabolism, almost always because a well-differentiated neuroendocrine tumor has spread to the liver or arises outside the portal circulation. Diagnosis rests on an elevated 24-hour urinary 5-HIAA with tumor localization by somatostatin-receptor PET, and management combines somatostatin analogues for symptom control and antiproliferative effect with tumor-directed therapy and peri-procedural crisis prevention.
- Celiac disease
Celiac disease is an immune-mediated small-intestinal enteropathy triggered by dietary gluten in genetically predisposed individuals, presenting with malabsorptive diarrhea, iron-deficiency anemia, or dermatitis herpetiformis. Diagnosis requires IgA tissue transglutaminase serology with a total IgA level while the patient still eats gluten, confirmed by duodenal biopsy showing villous atrophy, and the only treatment is a strict lifelong gluten-free diet.